Nitroaryl Phosphoramides as Novel Prodrugs for E. coli Nitroreductase Activation in Enzyme Prodrug Therapy

Journal of Medicinal Chemistry

Volumn 46, Issue 23, 2003, Pages 4818-4821

  Hu, Longqin ^a   Yu, Chengzhi ^a   Jiang, Yongying ^a   Han, Jiye ^a   Li, Zhuorong ^a   Browne, Patrick ^b   Race, Paul R ^c   Knox, Richard J ^b   Searle, Peter F ^c   Hyde, Eva I ^c  

^a RUTGERS UNIVERSITY   (United States)

^b Enact Pharma PLC   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROBENZYLPHOSPHORAMIDE MUSTARD; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; AROMATIC NITRO COMPOUND; DINITROBENZYLBENZAMIDE MUSTARD; INDOLE DERIVATIVE; NITROBENZENE DERIVATIVE; NITROINDOLE; PHOSPHORAMIDIC ACID DERIVATIVE; SN 23862; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CELL STRAIN V 79; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IC 50; NONHUMAN;

EID: 0242299595     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034133h     Document Type: Article

References (22)

1. Pochopin, N. L.; Charman, W. N.; Stella, V. J. Amino acid derivatives of dapsone as water-soluble prodrugs. Int. J. Pharmaceut. 1995, 121, 157-167.
2. Oliyai, R.; Stella, V. J. Prodrugs of peptides and proteins for improved formulation and delivery. Annu. Rev. Pharmacol. Toxicol. 1993, 32, 521-544.
3. Bundgaard, H. Design of Prodrugs; Elsevier: Amsterdam, 1985; 357.
4. Melton, R. G.; Knox, R. J. Enzyme-prodrug strategies for cancer therapy; Kluwer Academic/Plenum: New York, 1999; p 272.
5. Bridgewater, J.; Minton, N. P.; Michael, N. P.; Knox, R.; Springer, C. et al. Expression of bacterial nitroreductase in mammalian cells renders them selectively sensitive to killing by CB 1954. Eur. J. Cancer 1995, 31, 2362-2370.
6. Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Coles, B.; Friedlos, F. et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992, 44, 2289-2295.
7. Knox, R. J.; Friedlos, F.; Sherwood, R. F.; Melton, R. G.; Anlezark, G. M. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 1992, 44, 2297-2301.
8. Denny, W. A. Nitroreductase-based GDEPT. Curr. Pharm. Design 2002, 8, 1349-1361.
9. Mulcahy, R. T.; Gipp, J. J.; Schmidt, J. P.; Joswig, C.; Borch, R. F. Nitrobenzyl phosphorodiamidates as potential hypoxia-selective alkylating agents. J. Med. Chem. 1994, 37, 1610-1615.
10. Borch, R. F.; Liu, J. W.; Schmidt, J. P.; Marakovits, J. T.; Joswig, C. et al. Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents. J. Med. Chem. 2000, 43, 2258-2265.
11. Hay, M. P.; Atwell, G. J.; Wilson, W. R.; Pullen, S. M.; Denny, W. A. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. J. Med. Chem. 2003, 46, 2456-2466.
12. Mauger, A. B.; Burke, P. J.; Somani, H. H.; Friedlos, F.; Knox, R. J. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjugation with a nitroreductase enzyme. J. Med. Chem. 1994, 37, 3452-3458.
13. Helsby, N. A.; Wheeler, S. J.; Pruijn, F. B.; Palmer, B. D.; Yang, S. J. et al. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: Distinct mechanisms of bioreductive activation. Chem. Res. Toxicol. 2003, 16, 469-478.
14. Chung-Faye, G.; Palmer, D.; Anderson, D.; Clark, J.; Downes, M. et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7, 2662-2668.
15. Zon, G. Cyclophosphamide analogues. Prog. Med. Chem. 1982, 19, 205-246.
16. Stec, W. J. Cyclophosphamide and its congers. J. Organophosphorous Chem. 1982, 13, 145-174.
17. Borch, R. F.; Millard, J. A. The mechanism of activation of 4-hydroxycyclophosphamide. J. Med. Chem. 1987, 30, 427-431.
18. Sykes, B. M.; Hay, M. P.; Bohinc-Herceg, D.; Helsby, N. A.; O'Connor, C. J. et al. Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates. J. Chem. Soc., Perkin Trans. 1 2000, 1601-1608.
19. Ludeman, S. M.; Zon, G. Synthesis and antitumor activity of cyclophosphamide analogues. 1. Benzo annulated cyclophosphamide and related systems. J. Med. Chem. 1975, 18, 1251-1253.
20. Li, Z.; Han, J.; Jiang, Y.; Browne, P.; Knox, R. J. et al. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. Bioorg. Med. Chem. 2003, 11, 4471-4478.
21. Grove, J. I.; Lovering, A. L.; Guise, C.; Race, P. R.; Wrighton, C. J. et al. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitisation to the prodrug CB1954. Cancer Res. 2003, 5532-5537.
22. Knox, R. J.; Friedlos, F.; Jarman, M.; Roberts, J. J. A new cytotoxic, DNA interstrand cross-linking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells. Biochem. Pharmacol. 1988, 37, 4661-4669.